Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Rosenberg Website

Steven A. Rosenberg, M.D., Ph.D.

Selected Publications

1)  Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, Parkhurst MR, Yang JC, Rosenberg SA.
Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.
Science. 344: 641-5, 2014.
2)  Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, Wunderlich JR, Mixon A, Farid S, Dudley ME, Hanada K, Almeida JR, Darko S, Douek DC, Yang JC, Rosenberg SA.
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors.
J. Clin. Invest. 124: 2246-59, 2014.
3)  Liu B, Zhong S, Malecek K, Johnson LA, Rosenberg SA, Zhu C, Krogsgaard M.
2D TCR-pMHC-CD8 kinetics determines T-cell responses in a self-antigen-specific TCR system.
Eur. J. Immunol. 44: 239-50, 2014.
4)  Dutton-Regester K, Gartner JJ, Emmanuel R, Qutob N, Davies MA, Gershenwald JE, Robinson W, Robinson S, Rosenberg SA, Scolyer RA, Mann GJ, Thompson JF, Hayward NK, Samuels Y.
A highly recurrent RPS27 5"UTR mutation in melanoma.
Oncotarget. 5: 2912-7, 2014.
5)  Abate-Daga D, Lagisetty KH, Tran E, Zheng Z, Gattinoni L, Yu Z, Burns WR, Miermont AM, Teper Y, Rudloff U, Restifo NP, Feldman SA, Rosenberg SA, Morgan RA.
A Novel Chimeric Antigen Receptor Against Prostate Stem Cell Antigen Mediates Tumor Destruction in a Humanized Mouse Model of Pancreatic Cancer.
Hum. Gene Ther. [Epub ahead of print], 2014.
6)  Rosati SF, Parkhurst MR, Hong Y, Zheng Z, Feldman SA, Rao M, Abate-Daga D, Beard RE, Xu H, Black MA, Robbins PF, Schrump DA, Rosenberg SA, Morgan RA.
A novel murine T-cell receptor targeting NY-ESO-1.
J. Immunother. 37: 135-46, 2014.
7)  Abate-Daga D, Speiser DE, Chinnasamy N, Zheng Z, Xu H, Feldman SA, Rosenberg SA, Morgan RA.
Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer.
PLoS ONE. 9: e93321, 2014.
8)  Beane JD, Yang JC, White D, Steinberg SM, Rosenberg SA, Rudloff U.
Efficacy of Adjuvant Radiation Therapy in the Treatment of Soft Tissue Sarcoma of the Extremity: 20-year Follow-Up of a Randomized Prospective Trial.
Ann. Surg. Oncol. [Epub ahead of print], 2014.
9)  Lu YC, Yao X, Crystal JS, Li YF, El-Gamil M, Gross C, Davis L, Dudley ME, Yang JC, Samuels Y, Rosenberg SA, Robbins PF.
Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions.
Clin. Cancer Res. 20: 3401-10, 2014.
10)  Sampson JH, Choi BD, Sanchez-Perez L, Suryadevara CM, Snyder DJ, Flores CT, Schmittling RJ, Nair SK, Reap EA, Norberg PK, Herndon JE, Kuan CT, Morgan RA, Rosenberg SA, Johnson LA.
EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss.
Clin. Cancer Res. 20: 972-84, 2014.
Click Here to View Expanded Bibliography.

This page was last updated on 7/9/2014.